Literature DB >> 21896768

Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice.

Kyu Yeong Choi1, Kai Chang, James M Pickel, John D Badger, Katherine W Roche.   

Abstract

Glutamate is the major excitatory neurotransmitter in the mammalian CNS and mediates fast synaptic transmission upon activation of glutamate-gated ion channels. In addition, glutamate modulates a variety of other synaptic responses and intracellular signaling by activating metabotropic glutamate receptors (mGluRs), which are G protein-coupled receptors. The mGluRs are also expressed in nonneuronal tissues and are implicated in a variety of normal biological functions as well as diseases. To study mGluR-activated calcium signaling in neurons, we generated mGluR5 transgenic animals using a Thy1 promoter to drive expression in the forebrain, and one founder unexpectedly developed melanoma. To directly investigate the role of mGluR5 in melanoma formation, we generated mGluR5 transgenic lines under a melanocyte-specific promoter, tyrosinase-related protein 1. A majority of the founders showed a severe phenotype with early onset. Hyperpigmentation of the pinnae and tail could be detected as early as 3-5 d after birth for most of the mGluR5 transgene-positive mice. There was 100% penetrance in the progeny from the tyrosinase-related protein 1-mGluR5 lines generated from founders that developed melanoma. Expression of mGluR5 was detected in melanoma samples by RT-PCR, immunoblotting, and immunohistochemistry. We evaluated the expression of several cancer-related proteins in tumor samples and observed a dramatic increase in the phosphorylation of ERK, implicating ERK as a downstream effector of mGluR5 signaling in tumors. Our findings show that mGluR5-mediated glutamatergic signaling can trigger melanoma in vivo. The aggressive growth and severe phenotype make these mouse lines unique and a potentially powerful tool for therapeutic studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21896768      PMCID: PMC3174576          DOI: 10.1073/pnas.1107304108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Metabotropic glutamate receptors.

Authors:  Francesco Ferraguti; Ryuichi Shigemoto
Journal:  Cell Tissue Res       Date:  2006-07-18       Impact factor: 5.249

Review 2.  The glutamatergic system outside the CNS and in cancer biology.

Authors:  Niki Kalariti; Nikos Pissimissis; Michael Koutsilieris
Journal:  Expert Opin Investig Drugs       Date:  2005-12       Impact factor: 6.206

3.  Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.

Authors:  Yarí E Marín; Jin Namkoong; Karine Cohen-Solal; Seung-Shick Shin; Jeffrey J Martino; Masahiro Oka; Suzie Chen
Journal:  Cell Signal       Date:  2005-11-21       Impact factor: 4.315

4.  Control of calcium oscillations by phosphorylation of metabotropic glutamate receptors.

Authors:  S Kawabata; R Tsutsumi; A Kohara; T Yamaguchi; S Nakanishi; M Okada
Journal:  Nature       Date:  1996-09-05       Impact factor: 49.962

5.  Grm5 expression is not required for the oncogenic role of Grm1 in melanocytes.

Authors:  Yarí E Marín; Jin Namkoong; Seung-Shick Shin; Jason Raines; Kurt Degenhardt; Eileen White; Suzie Chen
Journal:  Neuropharmacology       Date:  2005       Impact factor: 5.250

6.  Clinical significance of metabotropic glutamate receptor 5 expression in oral squamous cell carcinoma.

Authors:  So-Yeon Park; Seoung-Ae Lee; In-Hee Han; Byong-Chul Yoo; Seung-Hoon Lee; Jo-Yong Park; In-Ho Cha; Jin Kim; Sung-Weon Choi
Journal:  Oncol Rep       Date:  2007-01       Impact factor: 3.906

7.  C-terminal ECFP fusion impairs synaptotagmin 1 function: crowding out synaptotagmin 1.

Authors:  Weiping Han; Jeong-Seop Rhee; Anton Maximov; Weichun Lin; Robert E Hammer; Christian Rosenmund; Thomas C Südhof
Journal:  J Biol Chem       Date:  2004-11-23       Impact factor: 5.157

8.  Development of heritable melanoma in transgenic mice.

Authors:  H Zhu; K Reuhl; X Zhang; R Botha; K Ryan; J Wei; S Chen
Journal:  J Invest Dermatol       Date:  1998-03       Impact factor: 8.551

9.  NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth.

Authors:  Andrzej Stepulak; Marco Sifringer; Wojciech Rzeski; Stefanie Endesfelder; Alexander Gratopp; Elena E Pohl; Petra Bittigau; Ursula Felderhoff-Mueser; Angela M Kaindl; Christoph Bührer; Henrik H Hansen; Marta Stryjecka-Zimmer; Lechoslaw Turski; Chrysanthy Ikonomidou
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-17       Impact factor: 11.205

10.  Spontaneous melanocytosis in transgenic mice.

Authors:  S Chen; H Zhu; W J Wetzel; M A Philbert
Journal:  J Invest Dermatol       Date:  1996-05       Impact factor: 8.551

View more
  48 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

Review 2.  Delving into somatic variation in sporadic melanoma.

Authors:  Vijay Walia; Euphemia W Mu; Jimmy C Lin; Yardena Samuels
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

Review 3.  Molecular pathways: dysregulated glutamatergic signaling pathways in cancer.

Authors:  Todd D Prickett; Yardena Samuels
Journal:  Clin Cancer Res       Date:  2012-05-30       Impact factor: 12.531

4.  Regulation of mGluR1 expression in human melanocytes and melanoma cells.

Authors:  Hwa Jin Lee; Brian A Wall; Janet Wangari-Talbot; Suzie Chen
Journal:  Biochim Biophys Acta       Date:  2012-07-05

Review 5.  Illuminating the Onco-GPCRome: Novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy.

Authors:  Victoria Wu; Huwate Yeerna; Nijiro Nohata; Joshua Chiou; Olivier Harismendy; Francesco Raimondi; Asuka Inoue; Robert B Russell; Pablo Tamayo; J Silvio Gutkind
Journal:  J Biol Chem       Date:  2019-06-05       Impact factor: 5.157

6.  PET imaging of metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Dan Li; Hong Shan; Peter Conti; Zibo Li
Journal:  Am J Nucl Med Mol Imaging       Date:  2011-12-15

7.  GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoid fibroma.

Authors:  Karolin H Nord; Henrik Lilljebjörn; Francesco Vezzi; Jenny Nilsson; Linda Magnusson; Johnbosco Tayebwa; Danielle de Jong; Judith V M G Bovée; Pancras C W Hogendoorn; Karoly Szuhai
Journal:  Nat Genet       Date:  2014-03-23       Impact factor: 38.330

8.  Targeting putative mu opioid/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model.

Authors:  Branden A Smeester; Mary M Lunzer; Eyup Akgün; Alvin J Beitz; Philip S Portoghese
Journal:  Eur J Pharmacol       Date:  2014-09-17       Impact factor: 4.432

9.  Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.

Authors:  Brian A Wall; Janet Wangari-Talbot; Seung S Shin; Devora Schiff; Jairo Sierra; Lumeng J Yu; Atif Khan; Bruce Haffty; James S Goydos; Suzie Chen
Journal:  Pigment Cell Melanoma Res       Date:  2014-01-22       Impact factor: 4.693

10.  A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

Authors:  Janice M Mehnert; Ann W Silk; J H Lee; Liesel Dudek; Byeong-Seon Jeong; Jiadong Li; Jason M Schenkel; Evita Sadimin; Michael Kane; Hongxia Lin; Weichung J Shih; Andrew Zloza; Suzie Chen; James S Goydos
Journal:  Pigment Cell Melanoma Res       Date:  2018-04-10       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.